{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T03:37:17Z","timestamp":1794800237777,"version":"4.9.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,4]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Acute myeloid leukemia with the t(8;21)(q22;q22) rearrangement (<jats:italic toggle=\"yes\">RUNX1-RUNX1T1<\/jats:italic> (+) AML) is known to have a favorable prognosis. Our study aimed to determine the most important prognostic variables among an aggregate of clinical, genetic, and treatment response-based factors in pediatric <jats:italic toggle=\"yes\">RUNX1-RUNX1T1<\/jats:italic> (+) AML.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Materials and Methods:<\/jats:title>\n            <jats:p>We analyzed the characteristics and outcome of 40 patients who were diagnosed with and treated for <jats:italic toggle=\"yes\">RUNX1-RUNX1T1<\/jats:italic> (+) AML from April 2008 to December 2016 at our institution.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>A&lt;\u22122.2 log fusion transcript decrement after remission induction, myeloid sarcoma type extramedullary involvement (EMI) at diagnosis, higher initial white blood cell count, and presence of <jats:italic toggle=\"yes\">KIT<\/jats:italic> mutation predicted lower event-free survival. Both lower fusion transcript decrement after remission induction and the presence of EMI at diagnosis proved to be significant adverse factors in the multivariate study. The 5-year event-free survival was 70.0\u00b17.2% (28\/40); 8 of the 12 relapsed patients survive disease-free, resulting in 5-year overall survival of 89.5\u00b15.0% (36\/40).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Kinetics of response to remission induction chemotherapy, measured in terms of the PCR value for the fusion transcript, and the presence of myeloid sarcoma type EMI at diagnosis may predict the risk of relapse in pediatric <jats:italic toggle=\"yes\">RUNX1-RUNX1T1<\/jats:italic> (+) AML.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mph.0000000000001623","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T19:25:02Z","timestamp":1572895502000},"page":"e132-e139","source":"Crossref","is-referenced-by-count":11,"title":["Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia"],"prefix":"10.1097","volume":"42","author":[{"given":"Jae Wook","family":"Lee","sequence":"first","affiliation":[{"name":"Pediatrics, Division of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongkoo","family":"Kim","sequence":"additional","affiliation":[{"name":"Pediatrics, Division of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pil-Sang","family":"Jang","sequence":"additional","affiliation":[{"name":"Pediatrics, Division of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nack-Gyun","family":"Chung","sequence":"additional","affiliation":[{"name":"Pediatrics, Division of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Cho","sequence":"additional","affiliation":[{"name":"Pediatrics, Division of Hematology and Oncology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Ah","family":"Im","sequence":"additional","affiliation":[{"name":"Radiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myungshin","family":"Kim","sequence":"additional","affiliation":[{"name":"Laboratory Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,10,29]]},"reference":[{"key":"R1-20230918","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1200\/JCO.2009.24.8997","article-title":"Cytogenetics of childhood acute myeloid leukemia: United Kingdom Medical Research Council Treatment trials AML 10 and 12","volume":"28","author":"Harrison","year":"2010","journal-title":"J Clin Oncol"},{"key":"R2-20230918","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S1470-2045(10)70090-5","article-title":"Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial","volume":"11","author":"Rubnitz","year":"2010","journal-title":"Lancet Oncol"},{"key":"R3-20230918","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1365-2141.2011.08851.x","article-title":"Results of a randomized trial in children with Acute Myeloid Leukaemia: medical research council AML12 trial","volume":"155","author":"Gibson","year":"2011","journal-title":"Br J Haematol"},{"key":"R4-20230918","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1038\/leu.2013.153","article-title":"Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children","volume":"27","author":"Tomizawa","year":"2013","journal-title":"Leukemia"},{"key":"R5-20230918","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1200\/JCO.2014.55.3628","article-title":"Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children\u2019s Oncology Group trial AAML0531","volume":"32","author":"Gamis","year":"2014","journal-title":"J Clin Oncol"},{"key":"R6-20230918","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/sj.leu.2402959","article-title":"Monitoring of minimal residual disease (MRD) by real-time quantitative reverse transcription PCR (RQ-RT-PCR) in childhood acute myeloid leukemia with AML1\/ETO rearrangement","volume":"17","author":"Viehmann","year":"2003","journal-title":"Leukemia"},{"key":"R7-20230918","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1002\/pbc.25109","article-title":"Monitoring the AML1\/ETO fusion transcript to predict outcome in childhood acute myeloid leukemia","volume":"61","author":"Zhang","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"R8-20230918","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.3324\/haematol.2014.114579","article-title":"Minimal residual disease monitored after induction therapy by RQ-PCR can contribute to tailor treatment of patients with t(8;21) RUNX1-RUNX1T1 rearrangement","volume":"100","author":"Pigazzi","year":"2015","journal-title":"Haematologica"},{"key":"R9-20230918","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1182\/blood-2009-09-241075","article-title":"Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML","volume":"115","author":"Pollard","year":"2010","journal-title":"Blood"},{"key":"R10-20230918","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1182\/blood-2005-08-3408","article-title":"KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group","volume":"107","author":"Shimada","year":"2006","journal-title":"Blood"},{"key":"R11-20230918","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/leu.2013.339","article-title":"Core-binding factor acute myeloid leukemia in pediatric patients enrolled in the AIEOP AML 2002\/01 trial: screening and prognostic impact of c-KIT mutations","volume":"28","author":"Manara","year":"2014","journal-title":"Leukemia"},{"key":"R12-20230918","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1038\/leu.2015.121","article-title":"Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia\/Lymphoma Study Group AML-05 trial","volume":"29","author":"Tokumasu","year":"2015","journal-title":"Leukemia"},{"key":"R13-20230918","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00043426-200310000-00004","article-title":"Extramedullary leukemia in children with newly diagnosed acute myeloid leukemia: a report from the Children\u2019s Cancer Group","volume":"25","author":"Dusenbery","year":"2003","journal-title":"J Pediatr Hematol Oncol"},{"key":"R14-20230918","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1002\/pbc.23201","article-title":"Superior outcome of pediatric acute myeloid leukemia patients with orbital and CNS myeloid sarcoma: a report from the Children\u2019s Oncology Group","volume":"58","author":"Johnston","year":"2012","journal-title":"Pediatr Blood Cancer"},{"key":"R15-20230918","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/sj.leu.2401971","article-title":"Extramedullary infiltrates at diagnosis have no prognostic significance in children with acute myeloid leukaemia","volume":"15","author":"Bisschop","year":"2001","journal-title":"Leukemia"},{"key":"R16-20230918","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1038\/sj.leu.2402449","article-title":"Orbital granulocytic sarcoma and AML with poor prognosis in Turkish children","volume":"16","author":"G\u00f6zda\u015fo\u011flu","year":"2002","journal-title":"Leukemia"},{"key":"R17-20230918","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/pbc.20824","article-title":"Extramedullary infiltration at diagnosis and prognosis in children with acute myelogenous leukemia","volume":"48","author":"Kobayashi","year":"2007","journal-title":"Pediatr Blood Cancer"},{"key":"R18-20230918","doi-asserted-by":"crossref","first-page":"e26520","DOI":"10.1002\/pbc.26520","article-title":"Extramedullary leukemia in children with acute myeloid leukemia: a population-based cohort study from the Nordic Society of Pediatric Hematology and Oncology (NOPHO)","volume":"64","author":"St\u00f8ve","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R19-20230918","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2141.2009.07580.x","article-title":"Aleukaemic acute myeloid leukaemia with t(8;21)(q22;q22)","volume":"146","author":"Wong","year":"2009","journal-title":"Br J Haematol"},{"key":"R20-20230918","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3345\/kjp.2013.56.6.247","article-title":"Utility of a multiplex reverse transcriptase-polymerase chain reaction assay (HemaVision) in the evaluation of genetic abnormalities in Korean children with acute leukemia: a single institution study","volume":"56","author":"Kim","year":"2013","journal-title":"Korean J Pediatr"},{"key":"R21-20230918","doi-asserted-by":"crossref","first-page":"e336","DOI":"10.1038\/bcj.2015.61","article-title":"Quantitative fragment analysis of FLT3-ITD efficiently identifying poor prognostic group with high mutant allele burden or long ITD length","volume":"5","author":"Kim","year":"2015","journal-title":"Blood Cancer J"},{"key":"R22-20230918","doi-asserted-by":"crossref","first-page":"e387","DOI":"10.1038\/bcj.2015.116","article-title":"Significance of KIT exon 17 mutation depends on mutant level rather than positivity in core-binding factor acute myeloid leukemia","volume":"6","author":"Jang","year":"2016","journal-title":"Blood Cancer J"},{"key":"R23-20230918","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1365-2141.1997.4763281.x","article-title":"Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia","volume":"99","author":"Parker","year":"1997","journal-title":"Br J Haematol"},{"key":"R24-20230918","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1038\/leu.2010.153","article-title":"Clinical significance of flowcytometric minimal residual disease detection in pediatric acute myeloid leukemia patients treated according to the DCOG ANLL97\/MRC AML12 protocol","volume":"24","author":"van der Velden","year":"2010","journal-title":"Leukemia"},{"key":"R25-20230918","first-page":"e1711","article-title":"Extramedullary relapse of acute myeloid and lymphoid leukemia in children: a retrospective analysis.","volume":"26","author":"Kim","year":"2016","journal-title":"Iran J Pediatr"},{"key":"R26-20230918","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.clml.2017.02.004","article-title":"Whole body MR imaging: a useful imaging modality in the management of children with acute myeloid leukemia","volume":"17","author":"Yoon","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"R27-20230918","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/10428194.2017.1361025","article-title":"KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia","volume":"59","author":"Chen","year":"2018","journal-title":"Leuk Lymphoma"},{"key":"R28-20230918","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1007\/s00277-017-3074-y","article-title":"D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations","volume":"96","author":"Yui","year":"2017","journal-title":"Ann Hematol"},{"key":"R29-20230918","doi-asserted-by":"crossref","first-page":"4447","DOI":"10.1002\/cam4.1733","article-title":"Core-binding factor acute myeloid leukemia with t(8;21): risk factors and a novel scoring system (I-CBFit)","volume":"7","author":"Ustun","year":"2018","journal-title":"Cancer Med"},{"key":"R30-20230918","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1038\/s41375-017-0003-y","article-title":"Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML","volume":"32","author":"Zampini","year":"2018","journal-title":"Leukemia"},{"key":"R31-20230918","doi-asserted-by":"crossref","first-page":"e26491","DOI":"10.1002\/pbc.26491","article-title":"Outcome of relapsed core binding factor acute myeloid leukemia in children: a result from the Japanese Pediatric Leukemia\/Lymphoma Study Group (JPLSG) AML-05R study","volume":"64","author":"Moritake","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"R32-20230918","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjh.12074","article-title":"Treatment of children with acute myeloid leukaemia who relapsed after allogeneic haematopoietic stem cell transplantation","volume":"160","author":"Lee","year":"2013","journal-title":"Br J Haematol"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001623","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T04:50:37Z","timestamp":1695012637000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MPH.0000000000001623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,29]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000001623","relation":{},"ISSN":["1077-4114"],"issn-type":[{"value":"1077-4114","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10,29]]}}}